Enveric Biosciences (NASDAQ:ENVB) Releases Earnings Results, Beats Expectations By $0.30 EPS

Enveric Biosciences (NASDAQ:ENVBGet Free Report) issued its earnings results on Monday. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.30, Yahoo Finance reports.

Enveric Biosciences Trading Down 7.8 %

ENVB stock traded down $0.04 during mid-day trading on Wednesday, reaching $0.49. The company’s stock had a trading volume of 162,555 shares, compared to its average volume of 2,381,886. The company’s 50 day moving average is $0.58 and its two-hundred day moving average is $0.83. Enveric Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $2.92. The stock has a market cap of $3.90 million, a PE ratio of -0.08 and a beta of 0.74.

Enveric Biosciences Company Profile

(Get Free Report)

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

Recommended Stories

Earnings History for Enveric Biosciences (NASDAQ:ENVB)

Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.